Nicotine carbomer enemas--pharmacokinetics of a revised formulation.
OBJECTIVE
Ulcerative colitis is predominantly a disease of non-smokers, and transdermal nicotine has therapeutic benefit but causes frequent side-effects. We have previously developed a topical enema combining nicotine with a polyacrylic carbomer; pharmacokinetic parameters were similar in healthy volunteers and patients with active ulcerative colitis. This enema was reformulated to reduce and delay nicotine absorption, thereby improving tolerance.


METHODS
Pharmacokinetic observations and side-effects with both formulations are compared in the same 8 healthy volunteers--all non-smokers, 3 male, mean age 33 years. Six milligrams of nicotine were complexed with 400 mg of carbomer in a 100 ml liquid enema. The original formulation was buffered with potassium/phosphate to pH 5.5, kinematic viscosity was 3 mNm; the revised preparation incorporated trometamol 1% solution to buffer to pH 4.2, viscosity 5 mNm. All subjects had the two formulations on separate occasions at least a month apart, with serial blood measurements and side-effect profile recorded for 8 hours.


RESULTS
The revised enema formulation significantly reduced Cmax for nicotine from 8.3 +/- 2.7 to 6.6 +/- 2.1, p = 0.03 with some reduction in nicotine absorption and improved tolerance. Although there was considerable intersubject variation in profiles for nicotine and cotinine, they were similar for each subject on both occasions.


CONCLUSIONS
The lower pH and greater viscosity reduced the amount of free nicotine in its unionised form available for absorption, but made it possible to expose colonic mucosa to the same nicotine dose. In other drug formulations where side-effects are a limiting factor these modifications may also be relevant.
Green
J T
JT
Department of Gastroenterology, University Hospital of Wales, Cardiff.
Rhodes
J
J
Thomas
G A
GA
Evans
B K
BK
Feyerabend
C
C
Russell
M A
MA
Sandborn
W J
WJ
D000180:Acrylic Resins; D000328:Adult; D002626:Chemistry, Pharmaceutical; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003367:Cotinine / Q000097:blood; D004337:Drug Carriers; D004733:Enema; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D009538:Nicotine / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011145:Polyvinyls
D000180:Acrylic Resins; D004337:Drug Carriers; D011145:Polyvinyls; C006912:carboxypolymethylene; D009538:Nicotine; D003367:Cotinine